Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Cyclerion Therapeutics, Inc. (CYCN)
USD3.71
-0.12 (-3.13%)
US NASDAQ Healthcare Biotechnology
Address
245 First Street 2142
Cambridge, MA, US
Cambridge, MA, US
CEO
Regina Graul
Website
cyclerion.com
IPO
2019-03-18
CIK 1755237 ISIN US23255M2044
Description
Cyclerion Therapeutics, Inc. operates as a biopharmaceutical company in the clinical development phase, concentrating on the discovery, advancement, and commercialization of therapeutic agents for debilitating central nervous system (CNS) disorders. Their leading experimental compound, CY6463, is a soluble guanylate cyclase (sGC) stimulator designed to cross the blood-brain barrier. It is presently in Phase IIa clinical assessments for managing mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), as well as Alzheimer's disease with vascular involvement. Concurrently, CY6463 is undergoing Phase 1 trials for treating schizophrenia in adult populations. The company's research portfolio also features other promising candidates: Praliciguat, an orally administered systemic sGC stimulator, is in Phase II studies targeting resistant hypertension and diabetic nephropathy. Olinciguat, another sGC stimulator designed for oral intake with a vascular focus, is progressing through Phase II trials for sickle cell disease. Moreover, CY3018 is under development to address a range of CNS ailments. Cyclerion holds a licensing agreement with Akebia Therapeutics, Inc., covering the entire lifecycle from development and manufacturing to medical affairs and commercialization for certain pharmaceutical compounds and related products. The company was founded in 2018 and has its principal place of business in Cambridge, Massachusetts.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD3.71
-0.12 (-3.13%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
199.7K
Beta
1.77
Float Shares
3.00M
Free Float %
69.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.31% | -0.31% | +9.28% | +162.81% | +123.94% | +150.39% | -1.85% | -28.70% | -94.61% | -98.73% | -98.73% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (2 ratings, all time)
Buy
Price Targets & DCF
Current price
3.71
DCF (Unlevered)
0.96
-74.1%
DCF (Levered)
0.58
-84.4%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-42.48
Distress
Piotroski F-Score
0 / 9
Weak
MOAT Score
2 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+3.7% ★ Q1'26: -100.0% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+9.9% Q1'26: -35.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-250.7%
-
EBIT margin Biotechnology: +0.0%-239.8%
-
ROIC Biotechnology: -16.1%-85.1%
-
Share dilution Biotechnology: -3.4%+28.1% Q1'26: +64.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
4.51M
est: 3.50M (+28.8%)
|
2.30M
est: 2.30M (-0.2%)
|
3.32M
est: 4.31M (-23.0%)
|
297.0K
est: 1.02M (-70.8%)
|
2.00M
est: 2.00M (+0.0%)
|
2.07M
est: 1.10M (+88.5%)
|
90.33M
90.33M – 90.33M
+8,111.9% YoY
|
586.1K
586.1K – 586.1K
-99.4% YoY
|
| EBITDA |
-122.34M
est: -2.10M (-5,725.6%)
|
-80.64M
est: -62.07M (-29.9%)
|
-53.84M
est: -2.59M (-1,982.3%)
|
-18.48M
est: -55.09M (+66.5%)
|
-3.63M
est: -1.20M (-202.3%)
|
-4.97M
est: -660.0K (-653.5%)
|
-54.20M
-54.20M – -54.20M
-8,111.9% YoY
|
-351.7K
-351.7K – -351.7K
+99.4% YoY
|
| EBIT |
-125.04M
est: -2.10M (-5,854.1%)
|
-82.93M
est: -84.04M (+1.3%)
|
-54.31M
est: -2.59M (-2,000.6%)
|
-18.54M
est: -71.70M (+74.1%)
|
-3.63M
est: -1.20M (-202.3%)
|
-4.97M
est: -660.0K (-653.5%)
|
-54.20M
-54.20M – -54.20M
-8,111.9% YoY
|
-351.7K
-351.7K – -351.7K
+99.4% YoY
|
| Net Income |
-123.01M
est: -249.28M (+50.7%)
|
-77.80M
est: -64.47M (-20.7%)
|
-51.65M
est: -69.50M (+25.7%)
|
-44.08M
est: -56.40M (+21.8%)
|
-3.06M
est: -75.54M (+96.0%)
|
-3.53M
est: -4.32M (+18.4%)
|
-3.87M
-3.87M – -3.87M
+10.4% YoY
|
-3.19M
-3.19M – -3.19M
+17.5% YoY
|
| SGA |
34.40M
est: 46.95M (-26.7%)
|
28.82M
est: 30.85M (-6.6%)
|
20.62M
est: 57.81M (-64.3%)
|
13.26M
est: 13.64M (-2.8%)
|
5.34M
est: 26.83M (-80.1%)
|
6.09M
est: 12.64M (-51.8%)
|
1.04B
1.04B – 1.04B
+8,111.9% YoY
|
6.74M
6.74M – 6.74M
-99.4% YoY
|
| EPS |
-88.37
est: -99.00 (+10.7%)
|
-47.80
est: -52.20 (+8.4%)
|
-26.40
est: -27.60 (+4.3%)
|
-20.15
est: -23.20 (+13.1%)
|
-1.21
est: -30.00 (+96.0%)
|
-1.09
est: -1.34 (+18.7%)
|
-1.20
-1.20 – -1.20
+10.4% YoY
|
-0.99
-0.99 – -0.99
+17.5% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-08 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-07 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-05 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-04 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-01 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-17 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-16 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-6.19M
OE per share TTM
-2.11
Owner's Yield
-60.17%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
916.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
2
Total invested
267.00
Insider transactions (90d)
0
Beneficial owners (>5%)
26
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | DAVID GREENSPAN | 7.16M | 16.50% | — | — | 7.16M | — | IN | — | 2022-10-21 | ↗ |
| 2 | JADES GP, LLC | 7.16M | 16.50% | — | — | 7.16M | — | OO | — | 2022-10-21 | ↗ |
| 3 | SLATE PATH CAPITAL LP | 7.16M | 16.50% | — | — | 7.16M | — | IA | — | 2022-10-21 | ↗ |
| 4 | SLATE PATH MASTER FUND LP | 7.16M | 16.50% | — | — | 7.16M | — | PN | — | 2022-10-21 | ↗ |
| 5 | Peter M. Hecht | 3.60M | 8.60% | 3.60M | — | 3.60M | — | IN | — | 2021-06-07 | ↗ |
| 6 | 2 | 3.39M | 7.80% | — | 3.39M | — | 3.39M | IN | Canada | 2022-02-09 | ↗ |
| 7 | Administratiekantoor Westend | 2.78M | 6.40% | 2.78M | — | 2.78M | — | OO | — | 2022-02-11 | ↗ |
| 8 | International Management S.A. | 2.78M | 6.40% | 2.78M | — | 2.78M | — | OO | — | 2022-02-11 | ↗ |
| 9 | International S.C.A. | 2.78M | 6.40% | 2.78M | — | 2.78M | — | OO | — | 2022-02-11 | ↗ |
| 10 | S.A. | 2.78M | 6.40% | 2.78M | — | 2.78M | — | OO | — | 2022-02-11 | ↗ |
| 11 | Wittouck | 2.78M | 6.40% | 2.78M | — | 2.78M | — | IN | — | 2022-02-11 | ↗ |
| 12 | Equities Advisors, LLC | 2.77M | 6.40% | 2.77M | — | 2.77M | — | OO | — | 2022-02-11 | ↗ |
| 13 | Equities, L.P. | 2.77M | 6.40% | 2.77M | — | 2.77M | — | PN | — | 2022-02-11 | ↗ |
| 14 | Limited | 2.77M | 6.40% | 2.77M | — | 2.77M | — | OO | — | 2022-02-11 | ↗ |
| 15 | 8.7% | 2.66M | 8.70% | 2.66M | — | 2.66M | — | CO | Ohio | 2020-02-14 | ↗ |
| 16 | 7.8% | 2.66M | 7.80% | 2.66M | — | 2.66M | — | CO | Ohio | 2021-02-05 | ↗ |
| 17 | Farhad Nanji | 2.43M | 7.15% | 2.43M | — | 2.43M | — | IN | Canada | 2021-02-12 | ↗ |
| 18 | MFN Partners GP, LLC | 2.43M | 7.15% | 2.43M | — | 2.43M | — | OO | Delaware | 2021-02-12 | ↗ |
| 19 | MFN Partners Management, LLC | 2.43M | 7.15% | 2.43M | — | 2.43M | — | OO | Delaware | 2021-02-12 | ↗ |
| 20 | MFN Partners Management, LP | 2.43M | 7.15% | 2.43M | — | 2.43M | — | IA | Delaware | 2021-02-12 | ↗ |
| 21 | MFN Partners, LP | 2.43M | 7.15% | 2.43M | — | 2.43M | — | PN | Delaware | 2021-02-12 | ↗ |
| 22 | Michael F. DeMichele | 2.43M | 7.15% | 2.43M | — | 2.43M | — | IN | United States | 2021-02-12 | ↗ |
| 23 | (1) BlackRock, Inc. | 1.58M | 4.70% | 1.56M | — | 1.58M | — | HC | Delaware | 2020-09-09 | ↗ |
| 24 | : Tyndall Capital Partners, LP | 121.6K | 5.05% | — | — | — | — | PN | Delaware | 2023-09-05 | ↗ |
| 25 | L.L.C. | 11.1K | 0.10% | 11.1K | — | 11.1K | — | OO | — | 2022-02-11 | ↗ |
| 26 | L.P. | 11.1K | 0.10% | 11.1K | — | 11.1K | — | PN | — | 2022-02-11 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
2
-17 vs prev Q
New positions
0
Closed positions
17
Increased
0
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | SIREN, L.L.C. | 115.6K -552.0 (-0.5%) | 146.8K -120.3K (-45.0%) | 3.58% -0.198 pp | 0.00% -0.006 pp | USD2.59 -51.0% | 6 qtrs — |
| 2 | GEODE CAPITAL MANAGEMENT, LLC | 43.3K +6.1K (+16.5%) | 55.0K -30.5K (-35.7%) | 1.34% +0.133 pp | 0.00% +0.000 pp | USD3.38 -62.4% | 11 qtrs — |
| 3 | TWO SIGMA INVESTMENTS, LP | 41.6K +28.3K (+212.6%) | 52.8K +22.2K (+72.6%) | 1.29% +0.856 pp | 0.00% +0.000 pp | USD1.60 -20.6% | 2 qtrs — |
| 4 | TWO SIGMA ADVISERS, LP | 28.3K +28.3K (+100.0%) | 35.9K +35.9K (+100.0%) | 0.88% +0.878 pp | 0.00% +0.000 pp | USD1.27 +0.0% | 1 qtrs NEW |
| 5 | VANGUARD GROUP INC | 23.5K +— (+0.0%) | 29.8K -24.2K (-44.8%) | 0.73% -0.037 pp | 0.00% +0.000 pp | USD4.12 -69.2% | 11 qtrs — |
| 6 | BLACKROCK, INC. | 16.8K +— (+0.0%) | 21.3K -17.3K (-44.8%) | 0.52% -0.026 pp | 0.00% +0.000 pp | USD2.59 -51.0% | 6 qtrs — |
| 7 | XTX TOPCO LTD | 10.0K +10.0K (+100.0%) | 12.7K +12.7K (+100.0%) | 0.31% +0.311 pp | 0.00% +0.000 pp | USD1.27 +0.0% | 1 qtrs NEW |
| 8 | CITIGROUP INC | 8.2K +8.2K (+100.0%) | 10.4K +10.4K (+100.0%) | 0.25% +0.254 pp | 0.00% +0.000 pp | USD1.27 +0.0% | 1 qtrs NEW |
| 9 | FMR LLC | 4.7K -6.0 (-0.1%) | 6.0K -4.9K (-44.9%) | 0.15% -0.008 pp | 0.00% +0.000 pp | USD4.05 -68.6% | 11 qtrs — |
| 10 | TOWER RESEARCH CAPITAL LLC (TRC) | 3.2K +826.0 (+35.5%) | 4.0K -1.3K (-25.2%) | 0.10% +0.022 pp | 0.00% 0.000 pp | USD2.45 -48.2% | 8 qtrs — |
| 11 | UBS GROUP AG | 376.00 +327.0 (+667.3%) | 478.00 +365.0 (+323.0%) | 0.01% +0.010 pp | 0.00% +0.000 pp | USD1.50 -15.3% | 11 qtrs — |
| 12 | GROUP ONE TRADING, L.P. | 192.00 +— (+0.0%) | 244.00 -198.0 (-44.8%) | 0.01% 0.000 pp | 0.00% +0.000 pp | USD4.11 -69.1% | 11 qtrs — |
| 13 | ADVISOR GROUP HOLDINGS, INC. | 130.00 +— (+0.0%) | 165.00 -139.0 (-45.7%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD3.22 -60.6% | 5 qtrs — |
| 14 | BANK OF AMERICA CORP /DE/ | 107.00 +85.0 (+386.4%) | 136.00 +86.0 (+172.0%) | 0.00% +0.003 pp | 0.00% +0.000 pp | USD1.50 -15.3% | 7 qtrs — |
| 15 | ACTIVEST WEALTH MANAGEMENT | 100.00 +— (+0.0%) | 127.00 -103.0 (-44.8%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD2.29 -44.5% | 7 qtrs — |
| 16 | MAI CAPITAL MANAGEMENT | 100.00 +— (+0.0%) | 127.00 -103.0 (-44.8%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD3.22 -60.6% | 5 qtrs — |
| 17 | — | 72.00 +72.0 (+100.0%) | 91.00 +91.0 (+100.0%) | 0.00% +0.002 pp | 0.00% +0.000 pp | USD1.26 +0.8% | 1 qtrs NEW |
| 18 | BNP PARIBAS ARBITRAGE, SNC | 5.00 +— (+0.0%) | 6.00 -6.0 (-50.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.20 -60.3% | 5 qtrs — |
| 19 | MORGAN STANLEY | 1.00 -648.0 (-99.8%) | 2.00 -1.5K (-99.9%) | 0.00% -0.021 pp | 0.00% +0.000 pp | USD4.00 -68.3% | 11 qtrs — |
| 20 | DRW SECURITIES, LLC | — -43.6K (-100.0%) | — -100.3K (-100.0%) | 0.00% -1.420 pp | 0.00% -0.002 pp | USD— | 2 qtrs SOLD |
| 21 | BARCLAYS PLC | — -5.0 (-100.0%) | — -12.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 5 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Fidelity Nasdaq Composite Index ETF ONEQ | 0.00% | 81.7K | 0.21% |
| 2 | Dimensional - US Sustainability Core 1 ETF DFSU | 0.00% | 13.1K | 0.15% |
| 3 | Vanguard Extended Market ETF VXF | 0.00% | 95.2K | 0.05% |
| 4 | Dimensional - US Core Equity 1 ETF DCOR | 0.00% | 3.0K | 0.14% |
| 5 | Dimensional - US Core Equity 2 ETF DFAC | 0.00% | 8.6K | 0.17% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
2
Sells
0
Shares acquired
190.9K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+190,908
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-08-07 | CHICKO RHONDA M. | Officer | A-Award | A | Stock Option (Right to Buy) | 25,000 | 2.36 | 58.9K | 25,000 | D | ↗ |
| 2025-03-25 | Higgins Michael J | Director | A-Award | A | Common Stock | 9,090 | 2.75 | 25.0K | 30,740 | D | ↗ |
| 2025-03-25 | Hecht Peter M | Director / 10% Owner | A-Award | A | Common Stock | 181,818 | 2.75 | 500.0K | 559,203 | D | ↗ |
| 2024-11-21 | Slate Path Capital LP | 10% Owner | S-Sale | D | Common Stock, no par value | 357,880 | 1.55 | 555.1K | 0 | I | ↗ |
| 2024-08-05 | Graul Regina Margaret | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 55,849 | 3.30 | 184.3K | 55,849 | — | ↗ |
| 2024-03-04 | CHICKO RHONDA M. | Officer | — | D | Common Stock | 0 | 0.00 | — | 18 | — | ↗ |
| 2024-01-01 | Hecht Peter M | Director / 10% Owner | A-Award | A | Common Stock | 15,000 | 0.00 | — | 377,385 | — | ↗ |
| 2024-01-01 | Graul Regina Margaret | Officer | A-Award | A | Common Stock | 50,000 | 0.00 | — | 100,303 | — | ↗ |
| 2023-12-01 | Hecht Peter M | Director / 10% Owner | A-Award | A | Common Stock | 15,000 | 0.00 | — | 362,385 | — | ↗ |
| 2023-12-01 | Graul Regina Margaret | Officer | — | D | Common Stock | 0 | 0.00 | — | 50,303 | — | ↗ |
| 2023-11-30 | MCGUIRE TERRANCE | Director | A-Award | A | Common Stock | 5,000 | 0.00 | — | 5,552 | — | ↗ |
| 2023-11-30 | Katabi Dina | Director | — | D | Common Stock | 0 | 0.00 | — | 20,000 | — | ↗ |
| 2023-11-30 | Hyman Steven | Director | A-Award | A | Common Stock | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2023-11-30 | Higgins Michael J | Director | — | D | Common Stock | 0 | 0.00 | — | 21,650 | — | ↗ |
| 2023-11-30 | Hecht Peter M | Director / 10% Owner | A-Award | A | Common Stock | 20,000 | 0.00 | — | 347,385 | — | ↗ |
| 2023-11-30 | DESOUZA ERROL B | Director | A-Award | A | Common Stock | 20,000 | 0.00 | — | 50,000 | — | ↗ |
| 2023-08-09 | MCGUIRE TERRANCE | Director | S-Sale | D | Common Stock | 8 | 3.40 | 27.16 | 0 | — | ↗ |
| 2023-05-19 | Hecht Peter M | Director / Officer / 10% Owner | A-Award | A | Common Stock | 225,000 | 8.68 | 1.95M | 327,385 | — | ↗ |
| 2022-07-25 | Hyman Steven | Director | A-Award | A | Stock Option (Right to Buy) | 57,753 | 0.78 | 45.0K | 57,753 | — | ↗ |
| 2022-06-14 | Mendelsohn Michael | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-06-14 | MCGUIRE TERRANCE | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-06-14 | Lovell Stephanie | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-06-14 | Isacson Ole | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-06-14 | Fanucci Marsha | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-06-14 | DESOUZA ERROL B | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-06-14 | CONRADES GEORGE H | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-01-20 | Hecht Peter M | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 430,000 | 1.21 | 520.3K | 430,000 | — | ↗ |
| 2022-01-20 | Gjino Anjeza | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 135,000 | 1.21 | 163.4K | 135,000 | — | ↗ |
| 2022-01-20 | Gault Cheryl | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 135,000 | 1.21 | 163.4K | 135,000 | — | ↗ |
| 2022-01-20 | Busch Andreas | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 135,000 | 1.21 | 163.4K | 135,000 | — | ↗ |
| 2022-01-03 | Hecht Peter M | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 52,950 | 1.78 | 94.3K | 52,950 | — | ↗ |
| 2021-12-09 | Gjino Anjeza | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 100,000 | 1.93 | 193.0K | 100,000 | — | ↗ |
| 2021-12-09 | Gault Cheryl | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 100,000 | 1.93 | 193.0K | 100,000 | — | ↗ |
| 2021-12-09 | Busch Andreas | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 75,000 | 1.93 | 144.8K | 75,000 | — | ↗ |
| 2021-06-24 | Mendelsohn Michael | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 3.97 | 39.7K | 10,000 | — | ↗ |
| 2021-06-24 | MCGUIRE TERRANCE | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 3.97 | 39.7K | 10,000 | — | ↗ |
| 2021-06-24 | Lovell Stephanie | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 3.97 | 39.7K | 10,000 | — | ↗ |
| 2021-06-24 | Isacson Ole | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 3.97 | 39.7K | 10,000 | — | ↗ |
| 2021-06-24 | Fanucci Marsha | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 3.97 | 39.7K | 10,000 | — | ↗ |
| 2021-06-24 | DESOUZA ERROL B | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 3.97 | 39.7K | 10,000 | — | ↗ |
| 2021-06-24 | Churchwell Kevin | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 3.97 | 39.7K | 10,000 | — | ↗ |
| 2021-06-24 | CONRADES GEORGE H | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 3.97 | 39.7K | 10,000 | — | ↗ |
| 2021-06-03 | Slate Path Capital LP | 10% Owner | P-Purchase | A | Common Stock, no par value | 961,538 | 3.12 | 3.00M | 7,157,601 | — | ↗ |
| 2021-06-03 | MCGUIRE TERRANCE | Director | P-Purchase | A | Common Stock | 3,322 | 3.12 | 10.4K | 24,957 | — | ↗ |
| 2021-06-03 | Hecht Peter M | Director / Officer | P-Purchase | A | Common Stock | 823,170 | 3.28 | 2.70M | 2,047,698 | — | ↗ |
| 2021-05-06 | Hecht Peter M | Director / Officer | P-Purchase | A | Common Stock | 302,000 | 2.43 | 733.9K | 1,224,528 | — | ↗ |
| 2021-05-05 | Hecht Peter M | Director / Officer | P-Purchase | A | Common Stock | 398,001 | 2.53 | 1.01M | 922,528 | — | ↗ |
| 2021-05-04 | Hecht Peter M | Director / Officer | P-Purchase | A | Common Stock | 300,000 | 2.29 | 687.0K | 524,527 | — | ↗ |
| 2021-04-21 | DESOUZA ERROL B | Director | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-02-25 | Wright Christopher I | Officer | S-Sale | D | Common Stock | 2,637 | 3.99 | 10.5K | 42,728 | — | ↗ |
| 2021-02-25 | Gjino Anjeza | Officer | S-Sale | D | Common Stock | 1,824 | 4.00 | 7.3K | 31,599 | — | ↗ |
| 2021-01-01 | Gjino Anjeza | Officer | — | D | Employee Stock Option (Right to Buy) | 3,773 | 11.28 | 42.6K | 0 | — | ↗ |
| 2021-01-01 | Gault Cheryl | Officer | — | D | Employee Stock Option (Right to Buy) | 1,588 | 17.31 | 27.5K | 0 | — | ↗ |
| 2020-12-28 | Currie Mark G | Officer | S-Sale | D | Common Stock | 20,107 | 3.01 | 60.5K | 251,648 | — | ↗ |
| 2020-12-16 | Wright Christopher I | Officer | — | D | Employee Stock Option (Right to Buy) | 75,000 | 2.01 | 150.8K | 0 | — | ↗ |
| 2020-11-09 | Busch Andreas | Officer | P-Purchase | A | Common Stock | 125,000 | 2.53 | 316.3K | 254,704 | — | ↗ |
| 2020-11-06 | Huyett William | Officer | S-Sale | D | Common Stock | 3,827 | 2.52 | 9.6K | 67,590 | — | ↗ |
| 2020-11-04 | Busch Andreas | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 75,000 | 2.48 | 186.0K | 75,000 | — | ↗ |
| 2020-07-29 | Slate Path Capital LP | 10% Owner | — | I | Common Stock, no par value | 0 | 0.00 | — | 6,196,063 | — | ↗ |
| 2020-06-16 | SCHULMAN AMY W | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 4.46 | 44.6K | 10,000 | — | ↗ |
| 2020-06-16 | Mendelsohn Michael | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 4.46 | 44.6K | 10,000 | — | ↗ |
| 2020-06-16 | MCGUIRE TERRANCE | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 4.46 | 44.6K | 10,000 | — | ↗ |
| 2020-06-16 | Lovell Stephanie | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 4.46 | 44.6K | 10,000 | — | ↗ |
| 2020-06-16 | Isacson Ole | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 4.46 | 44.6K | 10,000 | — | ↗ |
| 2020-06-16 | Fanucci Marsha | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 4.46 | 44.6K | 10,000 | — | ↗ |
| 2020-06-16 | Churchwell Kevin | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 4.46 | 44.6K | 10,000 | — | ↗ |
| 2020-06-16 | CONRADES GEORGE H | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 4.46 | 44.6K | 10,000 | — | ↗ |
| 2020-03-31 | Hecht Peter M | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 153,846 | 2.65 | 407.7K | 153,846 | — | ↗ |
| 2020-02-21 | Huyett William | Officer | S-Sale | D | Common Stock | 3,559 | 5.12 | 18.2K | 71,417 | — | ↗ |
| 2019-12-30 | Currie Mark G | Officer | S-Sale | D | Common Stock | 25,000 | 2.48 | 62.0K | 271,755 | — | ↗ |
| 2019-12-27 | Currie Mark G | Officer | S-Sale | D | Common Stock | 25,000 | 2.55 | 63.8K | 296,755 | — | ↗ |
| 2019-11-22 | Huyett William | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 75,000 | 2.01 | 150.8K | 75,000 | — | ↗ |
| 2019-11-22 | Hecht Peter M | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 75,000 | 2.01 | 150.8K | 75,000 | — | ↗ |
| 2019-11-22 | Currie Mark G | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 75,000 | 2.01 | 150.8K | 75,000 | — | ↗ |
| 2019-11-22 | Busch Andreas | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 75,000 | 2.01 | 150.8K | 75,000 | — | ↗ |
| 2019-11-15 | Busch Andreas | Officer | P-Purchase | A | Common Stock | 125,000 | 1.82 | 227.5K | 125,000 | — | ↗ |
| 2019-11-08 | Huyett William | Officer | S-Sale | D | Common Stock | 3,922 | 2.05 | 8.0K | 74,976 | — | ↗ |
| 2019-07-10 | Hecht Peter M | Director / Officer | M-Exempt | D | Employee Stock Option (Right to Buy) | 2,000 | 6.04 | 12.1K | 0 | — | ↗ |
| 2019-06-01 | SCHULMAN AMY W | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 13.95 | 139.5K | 10,000 | — | ↗ |
| 2019-06-01 | Mendelsohn Michael | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 13.95 | 139.5K | 10,000 | — | ↗ |
| 2019-06-01 | MCGUIRE TERRANCE | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 13.95 | 139.5K | 10,000 | — | ↗ |
| 2019-06-01 | Lovell Stephanie | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 13.95 | 139.5K | 10,000 | — | ↗ |
| 2019-06-01 | Isacson Ole | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 13.95 | 139.5K | 10,000 | — | ↗ |
| 2019-06-01 | Fanucci Marsha | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 13.95 | 139.5K | 10,000 | — | ↗ |
| 2019-06-01 | Churchwell Kevin | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 13.95 | 139.5K | 10,000 | — | ↗ |
| 2019-06-01 | CONRADES GEORGE H | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 13.95 | 139.5K | 10,000 | — | ↗ |
| 2019-04-29 | Busch Andreas | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 300,000 | 15.40 | 4.62M | 300,000 | — | ↗ |
| 2019-04-08 | SCHULMAN AMY W | Director | P-Purchase | A | Common Stock | 604,482 | 16.00 | 9.67M | 604,482 | — | ↗ |
| 2019-04-08 | MCGUIRE TERRANCE | Director | P-Purchase | A | Common Stock | 604,482 | 16.00 | 9.67M | 604,482 | — | ↗ |
| 2019-04-02 | Currie Mark G | Officer | P-Purchase | A | Common Stock | 270,107 | 14.81 | 4.00M | 321,755 | — | ↗ |
| 2019-04-01 | SCHULMAN AMY W | Director | A-Award | A | Common Stock | 4,229 | 0.00 | — | 4,229 | — | ↗ |
| 2019-04-01 | Mendelsohn Michael | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-04-01 | MCGUIRE TERRANCE | Director | A-Award | A | Common Stock | 6,911 | 0.00 | — | 6,911 | — | ↗ |
| 2019-04-01 | Lovell Stephanie | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-04-01 | Isacson Ole | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-04-01 | IRONWOOD PHARMACEUTICALS INC | 10% Owner | J-Other | D | Common Stock | 15,562,555 | 0.00 | — | 0 | — | ↗ |
| 2019-04-01 | Huyett William | Officer | A-Award | A | Common Stock | 38,327 | 0.00 | — | 38,327 | — | ↗ |
| 2019-04-01 | Hecht Peter M | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-04-01 | Fanucci Marsha | Director | A-Award | A | Common Stock | 13,671 | 0.00 | — | 13,671 | — | ↗ |
| 2019-04-01 | Currie Mark G | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 9,930 | 15.54 | 154.3K | 9,930 | — | ↗ |
| 2019-04-01 | Churchwell Kevin | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-04-01 | CONRADES GEORGE H | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-03-29 | IRONWOOD PHARMACEUTICALS INC | 10% Owner | A-Award | A | Common Stock | 15,562,455 | 0.00 | — | 15,562,555 | — | ↗ |
| 2019-03-14 | IRONWOOD PHARMACEUTICALS INC | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 100 | — | ↗ |
| 2019-03-14 | Huyett William | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-03-14 | Fanucci Marsha | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-03-14 | Consylman Gina | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-49.7K
Shares Outstanding
4.33M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Regina M. Graul, Ph.D. President and Chief Executive Officer | 390.8K | 125.0K | 323.7K | — | — | 35.3K | 874.8K | 37.00% | ↗ |
| 2 | 2024 | Rhonda M. Chicko Chief Financial Officer and Corporate Secretary | 249.9K | — | — | — | — | — | 249.9K | 0.00% | ↗ |
| 3 | 2023 | Anjeza Gjino Chief Financial Officer and Corporate Secretary | 365.5K | 238.0K | — | — | — | 24.2K | 853.7K | 0.00% | ↗ |
| 4 | 2023 | Cheryl Gault Chief Operating Officer | 255.2K | 246.0K | — | — | — | 42.4K | 757.6K | 0.00% | ↗ |
| 5 | 2023 | Regina Graul President | 31.0K | — | 124.3K | — | — | — | 155.3K | 80.04% | ↗ |
| 6 | 2023 | Regina M. Graul, Ph.D. President and Chief Executive Officer | 31.0K | — | 124.3K | — | — | — | 155.3K | 80.04% | ↗ |
| 7 | 2023 | Peter Hecht, Ph.D. Chief Executive Officer | 65.4K | — | — | — | — | 17.6K | 83.0K | 0.00% | ↗ |
| 8 | 2022 | Cheryl Gault Chief Operating Officer | 427.4K | 85.5K | 128.0K | — | — | 3.7K | 644.6K | 19.86% | ↗ |
| 9 | 2022 | Anjeza Gjino Chief Financial Officer and Corporate Secretary | 407.7K | 81.5K | 128.0K | — | — | 8.2K | 625.4K | 20.47% | ↗ |
| 10 | 2022 | Peter Hecht, Ph.D., Chief Executive Officer | 100.0K | — | — | 481.7K | — | 8.6K | 590.3K | 81.61% | ↗ |
| 11 | 2022 | Peter Hecht, Ph.D. Chief Executive Officer | 100.0K | — | 481.7K | — | — | 8.6K | 590.3K | 81.61% | ↗ |
| 12 | 2021 | Andreas Busch, Ph.D., Chief Scientific Officer | 492.3K | — | — | 113.2K | 135.9K | 41.1K | 782.5K | 14.46% | ↗ |
| 13 | 2021 | Cheryl Gault Chief Operating Officer | 394.6K | — | — | 150.9K | 110.6K | 8.2K | 664.3K | 22.72% | ↗ |
| 14 | 2021 | Peter Hecht, Ph.D., Chief Executive Officer | 100.0K | — | — | — | — | 8.2K | 108.2K | 0.00% | ↗ |
| 15 | 2021 | Peter M. Hecht, Ph.D., Chief Executive Officer | 100.0K | — | — | — | — | 8.2K | 108.2K | 0.00% | ↗ |
| 16 | 2020 | Andreas Busch, Ph.D., Chief Scientific Officer | 479.7K | — | — | 144.5K | 138.1K | 44.6K | 806.9K | 17.91% | ↗ |
| 17 | 2020 | Christopher Wright, M.D., Ph.D, Chief Medical Officer | 456.1K | — | — | 144.5K | 158.3K | 8.1K | 767.1K | 18.84% | ↗ |
| 18 | 2020 | Peter M. Hecht, Ph.D., Chief Executive Officer | 103.8K | — | — | 255.2K | — | 6.9K | 366.0K | 69.73% | ↗ |
| 19 | 2020 | Peter M.Hecht, Ph.D., Chief Executive Officer | 103.8K | — | — | 255.2K | — | 6.9K | 366.0K | 69.73% | ↗ |
| 20 | 2019 | Andreas Busch, Ph.D., Chief Scientific Officer | 306.2K | — | — | 2.88M | — | 67.8K | 3.25M | 88.50% | ↗ |
| 21 | 2019 | Peter M.Hecht, Ph.D., Chief Executive Officer | 71.2K | — | — | 48.9K | — | 1.6K | 121.6K | 40.20% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Regina Graul | Chief Executive Officer, President & Director | 551.2K | — |
| Rhonda Chicko | Chief Financial Officer | 249.9K | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CYCN
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
